DOI: https://doi.org/10.22141/2224-0721.8.72.2015.72335

Application of the Original L-Ornithine-L-Aspartate in Patients with Complex Cardiovascular Disease and Type 2 Diabetes Mellitus

V.Yu. Zharynova, K.N. Ihrunova, L.A. Bodretska, V.P. Chyzhova, I.A. Samots, Zh.S. Butynets, A.Yu. Haletskyi, N.N. Benkovska, V.O. Tabakovych-Vatseba

Abstract


The article deals with the treatment of nonalcoholic fatty liver disease as a complication in patients with complex cardiovascular disease and type 2 diabetes mellitus. The data from the studies on the effect of Hepa-Merz® on the functional state of the liver, endothelium, blood rheology, the state of the capillary circulation, endotoxemia markers and clinical status in these patients are presented. The findings confirm the possibility of the influence of Hepa-Merz® on the functional disorders of the liver in patients with complex cardiovascular disease and type 2 diabetes mellitus.


Keywords


diabetes mellitus; cardiovascular disease; hepatoprotectors; non-alcoholic fatty liver disease

References


Мубаракшина О.А. Гепатопротекторы: сравнительная характеристика и аспекты клинического использования // Медицинский вестник. — 2008. — № 34.

Оковитый С.В. Клиническая фармакология гепатопротекторов // Практик. — 2002. — № 3.

Передерий В.Г., Чернявский В.В., Шипулин В.П. Сравнительная эффективность применения гепатопротекторов при хронических диффузных заболеваниях печени // Сучасна гастроентерологія. — 2008. — № 3. — С. 81-83.

Arab J.P., Candia R., Zapata R. et al. Management of nonalcoholic fatty liver disease:an evidence-based clinical practice review // World J. Gastroenterol. — 2014. — 20 (34). — 12182-201. doi:10.3748/wjg.v20.i34.12182.

Bass N.M., Mullen K.D., Sanyal A. et al. Rifaximin treatment in hepatic encephalopathy // New England Journal of Medicine. — 2010. — 362 (12). — 1071-1081.

Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults // J. Clin. Gastroenterol. — 2006 Mar. — 40, Suppl. 1. — S5-10.

Córdoba J., López-Hellín J., Planas M. et al. Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study // J. Hepatol. — 2004. — 41. — 38-43.

Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis // Hepatology. — 2006 Feb. — 43 (2, Suppl. 1). — S99-S11.

Jalan R., Wright G., Davies N.A., Hodges S.J. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy // Med. Hypotheses. — 2007. — 69. — 1064-69.

Leise M., Poterucha J., Kamath P. Management of Hepatic Encephalopathy in the Hospital // Clin. Proc. — 2014. — 89 (2). — 241-253.

Malaguarnera M., Gargante M.P., Cristaldi E. et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy // Digestive Diseases and Sciences. — 2008. — 53 (11). — 3018-3025.

McPhail M., Leech R., Grover V. et al. Modulation of neural activation following treatment of hepatic encephalopathy // Neurology. — 2013. — 80 (11). — P. 1041-1047.

Miyake M., Kirisako T. Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers // Nutr. J. — 2014. — 13. — P. 53-55.

Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference // Hepatology. — 2003. — 37 (5). — 1202-1219.

Ong J.P., Elariny H., Collantes R. et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients // Obes. Surg. — 2005 Mar. — 15 (3). — 310-5.

Rinella M.E. Nonalcoholic fatty liver disease: a systematic review // JAMA. — 2015 Jun 9. — 313 (22). — 2263-73. doi:10.1001/jama.2015.5370.

Sharma P., Sharma B.C., Puri V., Sarin S.K. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy // European Journal of Gastroenterology and Hepatology. — 2008. — 20 (6). — 506-511.

Skowrońska M., Albrecht J. Alteration of blood brain barrier function in hyperammonemia // Neurotox. res. — 2012. — 21 (2). — P. 236-244.

Thompson J.R. Treatment guidelines for hepatic encephalopathy // Pharmacotherapy. — 2010. — 30 (5). — 4S-9S.

Zhang Y., Janssen P., WinglerK. et al. Modulating endothelial nitric oxide synthase:a new cardiovascular therapeutic strategy // Am. J. Physiol. Heart Circ. Physiol. — 2011. — 301. — H634-H646.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта